Press Releases

Immunomic Therapeutics, Inc., (“ITI”), a privately-held clinical-stage biotechnology company pioneering the study of nucleic acid immunotherapy platforms and Ichor Medical Systems (“Ichor”), a privately held biotech company based in San Diego, CA, announced today that the companies have entered into a license agreement to support the development of ITI’s investigational plasmid DNA vaccine therapy, ITI-1001. ITI will leverage Ichor’s TriGrid®

VerifyMe, Inc., a digital technology solutions provider specializing in counterfeit prevention, authentication, serialization, data mining, track and trace, features for labels, packaging and products, is pleased to announce that it has entered into a strategic relationship with Techind Engineers & Consultants-Impex ("Techind"), part of the Gohar Group, of India. Techind has experience in serialization and track and trace, having sold and installed more than 100 produc

Medison Pharma Trading AG, a fully owned subsidiary of Medison Pharma Ltd., and Alpha Tau Medical Ltd., the developer of a breakthrough alpha-radiation cancer therapy "Alpha DaRT," are pleased to announce an exploratory collaboration in the oncology field in Central and Eastern Europe. Medison is a specialized pharmaceutical and biotech company focused on licensing highly innovative, cutting edge therapeutics for patients in need of life-saving therapies in various international mar

Solasia Pharma K.K., a specialty pharmaceutical company based in Asia, today announced the positive results from the pivotal Phase 2 study with SP-02 (a new anti-cancer drug, international generic name: darinaparsin, hereinafter “darinaparsin”) for relapsed or refractory peripheral T-cell lymphoma (hereinafter “PTCL”) in Asia. The primary endpoint (antitumor effect) was achieved. No new safety concerns were identified in the safety analysis

The U.S. Food and Drug Administration approved Tivicay (dolutegravir) tablets and Tivicay PD (dolutegravir) tablets for suspension to treat HIV-1 infection in pediatric patients at least four weeks old and weighing at least 3 kg (6.61 pounds) in combination with other antiretroviral treatments. "For babies and young children with HIV, getting treatment early is very important. HIV can progress more quickly in children than adults," said Debra Birnkrant, M.D., director of t

Leap Therapeutics, Inc., a biotechnology company focused on developing targeted and immuno-oncology therapeutics,  announced that the U.S. Food and Drug Administration (FDA) has granted the Company orphan drug designation for DKN-01 for the treatment of gastric and gastroesophageal junction cancer. DKN-01 is a humanized monoclonal antibody that binds to and blocks the activity of the Dickkopf-1 (DKK1) protein, a modulator of Wnt/Beta-catenin signaling. "Orphan Drug Designa

The U.S. Food and Drug Administration  approved Uplizna (inebilizumab-cdon) injection for intravenous use for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients with a particular antibody (patients who are anti-aquaporin-4 or AQP4 antibody positive). NMOSD is a rare autoimmune disease of the central nervous system that mainly affects the optic nerves and spinal cord. Uplizna is only the second approved treatment for the disorder. "Until recen

Adagene Incorporated, a precision antibody engineering, discovery and development company, and Tanabe Research Laboratories U.S.A., Inc. (TRL), a subsidiary of Mitsubishi Tanabe Pharma Corporation (MTPC), today announced that the companies have entered into a strategic collaboration under which TRL will use Adagene's SAFEbody™ technology platform to generate a masked antibody in combination with the cytotoxic payload technologies used at TRL, for the development of an ADC against a

Informa, the organisers of the leading regional pharmaceutical event CPhI Middle East & Africa, has announced that due to the COVID-19 pandemic, the 2020 edition of the show, scheduled to take place in September in Abu Dhabi, has been cancelled. A new earlier date and location for the event has been disclosed, with the show debuting in Riyadh, Saudi Arabia on March 2021. CPhI Middle East & Africa 2021 will be held at a time when the MENA pharmaceutical market is experiencing

UbiVac, Inc. announced it has entered into a clinical trial collaboration with Bristol Myers Squibb (NYSE:BMY) to evaluate the safety, tolerability, and preliminary efficacy of UbiVac’s investigational product, DPV-001™, a first-in-class cancer vaccine that exploits autophagy, in combination with Bristol Myers Squibb’s anti-OX40 (BMS-986178) combined with sequenced administration of the programmed death-1 (PD-1) immune checkpoint inhibitor, Opdivo (nivolumab). The Phase 1b m